Abstract
Spinal cord trauma activates the immune system and elicits leukocyte recruitment to the site of injury. This increase in immunological activity contributes to acute lesion expansion over a period of days to weeks following the initial trauma. At the same time, inflammatory cells and mediators facilitate endogenous repair processes such as axonal sprouting and remyelination. Thus, to be effective, therapies that target the immune system must limit the destructive effects of neutrophil, macrophage and lymphocyte activation, while simultaneously preserving their reparative functions.
Keywords: inflammation, spinal cord injury, neuroprotection, immunology, pathology
Current Pharmaceutical Design
Title: Inflammatory-Mediated Injury and Repair in the Traumatically Injured Spinal Cord
Volume: 11 Issue: 10
Author(s): T. B. Jones, E. E. McDaniel and P. G. Popovich
Affiliation:
Keywords: inflammation, spinal cord injury, neuroprotection, immunology, pathology
Abstract: Spinal cord trauma activates the immune system and elicits leukocyte recruitment to the site of injury. This increase in immunological activity contributes to acute lesion expansion over a period of days to weeks following the initial trauma. At the same time, inflammatory cells and mediators facilitate endogenous repair processes such as axonal sprouting and remyelination. Thus, to be effective, therapies that target the immune system must limit the destructive effects of neutrophil, macrophage and lymphocyte activation, while simultaneously preserving their reparative functions.
Export Options
About this article
Cite this article as:
Jones B. T., McDaniel E. E. and Popovich G. P., Inflammatory-Mediated Injury and Repair in the Traumatically Injured Spinal Cord, Current Pharmaceutical Design 2005; 11 (10) . https://dx.doi.org/10.2174/1381612053507468
DOI https://dx.doi.org/10.2174/1381612053507468 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Therapy in Brugada Syndrome
Current Drug Targets - Cardiovascular & Hematological Disorders GABA Puts a Stop to Pain
Current Drug Targets - CNS & Neurological Disorders Changing the Course of Alzheimers Disease: Emerging Disease Modifying Therapies
Current Psychiatry Reviews Combinatorial Approaches for the Identification of Brain Drug Delivery Targets
Current Pharmaceutical Design Battle for Pluripotency: Derivation of Induced Pluripotent Stem Cells
Recent Patents on Regenerative Medicine Drugs of Abuse-Induced Hyperthermia, Blood-Brain Barrier Dysfunction and Neurotoxicity: Neuroprotective Effects of a New Antioxidant Compound H-290/51
Current Pharmaceutical Design Non-Analgesic Effects of Opioids: Neuroprotection in the Retina
Current Pharmaceutical Design Locus (Coeruleus) Minoris Resistentiae in Pathogenesis of Alzheimer’s Disease
Current Alzheimer Research Protective Effects of Melatonin and Mitochondria-targeted Antioxidants Against Oxidative Stress: A Review
Current Medicinal Chemistry Neurovascular Mechanisms of Hypertension in Pregnancy
Current Neurovascular Research An Intricate Mechanism of Action of Avonex in Relapsing Remitting Multiple Sclerosis Patients: Variation of Serum Titre of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-β
CNS & Neurological Disorders - Drug Targets Angiopoietin-1 and C16 Peptide Attenuate Vascular and Inflammatory Responses in Experimental Allergic Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology Editorial [Hot topic: Endocannabinoid Signaling and Neuroinflammatory Diseases (Executive Editor: Mauro Maccarrone)]
Current Pharmaceutical Design Commonalities in Biological Pathways, Genetics, and Cellular Mechanism between Alzheimer Disease and Other Neurodegenerative Diseases: An In Silico-Updated Overview
Current Alzheimer Research The Trigeminal System in Birds and Nociception
Central Nervous System Agents in Medicinal Chemistry Human Neural Stem and Progenitor Cells: In Vitro and In Vivo Properties, and Potential for Gene Therapy and Cell Replacement in the CNS
Current Gene Therapy Biomarker-Guided Strategy for Treatment of Autism Spectrum Disorder (ASD)
CNS & Neurological Disorders - Drug Targets HSV Amplicons: Neuro Applications
Current Gene Therapy From A1 to A3 en passant Through A2A Receptors in the Hippocampus: Pharmacological Implications
CNS & Neurological Disorders - Drug Targets